Additional file 1: of XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance

Figure S1. Colony formation in shCon or shXLF cells treated with DMSO, cisplatin, cisplatin + L189 (LIG4 inhibitor), oxaliplatin, or oxaliplatin + L189, respectively. Figure S2. Genomic alteration frequency of core factors of NHEJ pathway (XLF, XRCC4, XRCC5, XRCC6, LIG4, PRKDC, TP53BP1, and DCLRE1C) was generated using cBioPortal [ http://www.cbioportal.org ] from database of TCGA (193 patients) and AMC (231 patients). Tumor types are indicated at the bottom and ordered by the frequency of samples harboring mutation, deletion, amplification and multiple alterations. Overall alteration frequency in liver cancer was highlighted. Figure S3. RNA-sequencing data organization of NHEJ pathway genes (XLF, XRCC4, XRCC5, XRCC6, LIG4, PRKDC, TP53BP1, and DCLRE1C) by TCGA to show frequency of NHEJ pathway gene amplification, gene expression, missense or truncating mutations. (ZIP 1521Â kb)